PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
暂无分享，去创建一个
W. Oyen | O. Hoekstra | P. Flamen | L. Ameye | A. Awada | S. Stroobants | J. Tol | E. Vries | A. Brouwers | G. V. Dongen | L. E. Lamberts | M. Huizing | G. Gebhart | P. Aftimos | C. W. Menke | T. Guiot | Z. Wimana | C. Schröder | C. Garcia | J. Gaye